Academy of Physicians
in Clinical Research

Academy of Physicians
in Clinical Research




News from SCRIP

APCR Members can get a free trial to SCRIP and a discount on a SCRIP subscription by contacting John Lezcano from SCRIP directly at the information below. 

John Lezcano
Corporate Account Manager

Pharma intelligence | informa
T: (212) 652-2678
M: (631) 807-4971
John.lezcano@informa.com
pharmaintelligence.informa.com

New Phase II Data Bolster vTv Therapeutics’ Glucokinase Activator Aspirations

Tue, 02/11/2020 - 9:04am

The future for glucokinase activation is looking a bit brighter with the results of the second phase of its Phase...

      Related Stories 

Diurnal Looking To Secure US Partner Soon For Alkindi

Tue, 02/11/2020 - 5:34am

With its adrenal insufficiency therapy Alkindi getting established in Europe, the UK biotech is in partnering discussions in the US...

      Related Stories 

Lupin US Launches On Track But Albuterol 'Clarity' Awaited

Mon, 02/10/2020 - 9:47pm

After lower growth in India business and impaired operations at five manufacturing units hit by US FDA action impacted Lupin's...

      Related Stories 

Troriluzole Fails First Phase III Test As Biohaven Looks Beyond Migraine

Mon, 02/10/2020 - 1:25pm

Biohaven is still studying its glutamate modulator in three other indications, but its biggest near-term milestone will be approval of...

      Related Stories 

Another Alzheimer's Setback As Roche And Lilly Drugs Fail

Mon, 02/10/2020 - 7:45am

As Biogen moves to file its controversial amyloid drug aducanumab for approval in the US, two similar investigational Alzheimer's drugs...

      Related Stories 

Woodford Woes Drag On For Immunocore

Mon, 02/10/2020 - 6:50am

Once seen as the champion of biotech start-ups, Woodford’s blind faith has shackled firms to unrealistic valuations.

      Related Stories 

Editor's Note: Join Our Survey To Shape Scrip's Future

Mon, 02/10/2020 - 3:49am

We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d...

      Related Stories 

Stockwatch: Gilead, BMS Expose High Cost Of M&A

Mon, 02/10/2020 - 3:43am

Expensive acquisitions are in the spotlight during earnings season. The purchases of Kite and Celgene by Gilead and Bristol-Myers Squibb...

      Related Stories 

Pipeline Watch: Approvals For Peanut Allergy, Pandemic Flu, Vaccines

Mon, 02/10/2020 - 2:56am

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies...

      Related Stories 

Coronavirus Notebook: China Focuses On Antivirals As Death Toll Passes SARS

Sun, 02/09/2020 - 9:31pm

Chief executives of two antiviral and vaccine developers share with Scrip their development plans and projections as the death toll...

      Related Stories 

Sun Sees Urgency To Establish Low Dose Absorica In US

Sun, 02/09/2020 - 8:07pm

Sun’s key specialty asset Ilumya makes progress, albeit slowly, in the US, while the firm sees ‘short window’ to ensure...

      Related Stories 

Zogenix’s Fintepla Reduces Drop Seizure Rates, But Is It Enough?

Fri, 02/07/2020 - 1:30pm

Despite positive Phase III results in Lennox-Gastaut syndrome, the effect of the company’s low-dose fenfluramine on serious seizures may not...

      Related Stories 

Countdown To The Allergan Merger, And More From AbbVie’s Q4 Earnings

Fri, 02/07/2020 - 1:07pm

Despite Humira’s ex-US sales erosion, AbbVie reports strong launches for Skyrizi and Rinvoq, continued growth for hematological oncology franchise, and...

      Related Stories 

Venture Funding Deals: Generation Bio Raises $110m For Non-Viral Gene Therapies

Fri, 02/07/2020 - 11:04am

Recent venture funding for emerging biopharma companies, including CF PharmTech, Codagenix, Empirico, Epirium, Generation, Kyverna, NorthSea, VectivBio, Rig and Tarsus. 

      Related Stories 

Pfizer’s Vyndaqel Success Interfering With Alnylam's Plans

Fri, 02/07/2020 - 7:15am

Alnylam wants to emulate success of Eylea and Revlimid in amyloidosis– but Pfizer could spoil the plan.

      Related Stories 

Orion Eyes US Market For Phase III ALS Therapy

Fri, 02/07/2020 - 6:22am

Sales grew but operating profits remained flat in 2019 at Orion Group, as the European mid-sized pharma pursued R&D in...

      Related Stories 

Lundbeck Set For 'Transformative' Eptinezumab Launch

Fri, 02/07/2020 - 5:23am

The Danish drugmaker's four 'strategic brands' – Brintellix, Abilify Maintena, Northera and Rexulti – are selling well. Now the focus...

      Related Stories 

GSK Has High Hopes For COPD Vaccine

Fri, 02/07/2020 - 1:34am

By combining its expertise in respiratory and vaccines, the UK drugs giant could have a potential blockbuster for chronic obstructive...

      Related Stories 

Pages